Until we better understand their action on the brain, its far too soon to call GLP-1 and GIP inhibitors miracle drugs for more conditions beyond type 2 diabetes and obesity. Even without the diagnosis of BED, up to 60% of people with obesity report experiencing food noise or thinking about food constantly which leads to distress and dysregulated eating behaviors, like loss of control eating and binge eating
More often, it comes from products that quietly support your skin day after day
We followed the BCS approach as it provides a surrogate for in vivo bioequivalence studies
Nestle has been producing these kinds of products for the elderly for decades (e.g
First, we emulated the two cardiovascular outcome trials SUSTAIN-6 (semaglutide versus placebo) and SURPASS-CVOT (tirzepatide versus dulaglutide) using the RCT-DUPLICATE approach to benchmark findings and inform the study design and analytic approach for expanded questions
On the other hand, individuals with type 2 diabetes or those who have struggled with weight loss despite other interventions may find GLP-1 medications beneficial
